...
首页> 外文期刊>International Journal of Pharmaceutics >The development of an inline Raman spectroscopic analysis method as a quality control tool for hot melt extruded ramipril fixed-dose combination products
【24h】

The development of an inline Raman spectroscopic analysis method as a quality control tool for hot melt extruded ramipril fixed-dose combination products

机译:作为热熔挤压ramipril固定剂组合产品的质量控制工具的inline拉曼光谱分析方法的发展

获取原文
获取原文并翻译 | 示例
           

摘要

Currently in the pharmaceutical industry, continuous manufacturing is an area of significant interest. In particular, hot-melt extrusion (HME) offers many advantages and has been shown to significantly reduce the number of processing steps relative to a conventional product manufacturing line. To control product quality during HME without process interruption, integration of inline analytical technology is critical. Vibrational spectroscopy (Raman, NIR and FT-IR) is often employed and used for real-time measurements because of the nondestructive and rapid nature of these analytical techniques. However, the establishment of reliable Process Analytical Technology (PAT) tools for HME of thermolabile drugs is challenging. Indeed, the Raman effect is inherently weak and might be subject to interference. Moreover, during HME, heating and photodecomposition can occur and disrupt spectra acquisition. The aim of this research article was to explore the use of inline Raman spectroscopy to characterise a thermolabile drug, ramipril (RMP), during continuous HME processing. Offline measurements by HPLC, LC-MS and Raman spectroscopy were used to characterise RMP and its main degradation product, ramipril-diketopiperazine (RMP-DKP, impurity K). A set of HME experiments together with inline Raman spectroscopic analyses were performed. The feasibility of implementing inline Raman spectroscopic analysis to quantify the level of RMP and RMP-DKP in the extrudate was addressed. Two regions in the Raman spectrum were selected to differentiate RMP and RMP-DKP. When regions were combined, a principle component analysis (PCA) model defined by these two main components (PC 1 = 50.1% and PC 2 = 45%) was established. Using HPLC analyses, we were able to confirm that the PC 1 score was attributed to the level of RMP-DKP, and the PC 2 score was related to the RMP drug content. Investigation of the PCA scatterplot indicated that HME processing temperature was not the only factor causing RMP degradation. Additionally, the plasticiser content, feeding speed and screw rotating speed contributed to RMP degradation during HME processing.
机译:目前在制药行业中,连续制造是一个重大兴趣的领域。特别地,热熔挤出(HME)提供了许多优点,并且已被证明可以显着降低相对于传统产品生产线的处理步骤的数量。为了在HME期间控制产品质量而无需过程中断,内联分析技术的集成至关重要。通常使用振动光谱(拉曼,NIR和FT-IR)并用于实时测量,因为这些分析技术的非破坏性和快速性质。然而,建立可靠的过程分析技术(PAT)用于HME的热栓塞药物的工具是挑战性的。实际上,拉曼效应本质上很弱,可能会受到干扰。此外,在HME期间,可以发生加热和光分解并破坏光谱采集。本研究制品的目的是探讨在连续HME处理期间使用内联拉曼光谱法,以表征热栓塞药物,RamiPRIL(RMP)。 HPLC,LC-MS和拉曼光谱的离线测量用于表征RMP及其主要降解产物,Ramipril-Diketopiperazine(RMP-DKP,杂质K)。进行一组与内联拉曼光谱分析的HME实验。解决了在线拉曼光谱分析以量化挤出物中RMP和RMP-DKP水平的可行性。选择拉曼光谱中的两个区域以区分RMP和RMP-DKP。结合区域时,建立了这两个主要成分(PC 1 = 50.1%和PC 2 = 45%)定义的原理分析(PCA)模型。使用HPLC分析,我们能够确认PC 1分数归因于RMP-DKP的水平,并且PC 2得分与RMP药物含量有关。研究PCA散点图表明HME加工温度不是导致RMP劣化的唯一因素。另外,增塑剂含量,进给速度和螺杆旋转速度导致HME加工过程中的RMP降解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号